New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

ConferenceNeutral

AI Analysis

Summary

Teva Pharmaceuticals presented new data from a discrete choice experiment at Psych Congress 2026 highlighting healthcare provider treatment preferences for VMAT2 inhibitors in treating tardive dyskinesia in older patients aged ≥55 years.

Importance:2/10

Sentiment:

0.00

TevaVMAT2 inhibitorTardive Dyskinesiahealthcare provider preferencesdiscrete choice experimentPsych Congress 2026

Related Companies

$TEVA

Read the original article

Published by GlobeNewswire Pharma on September 18, 2026 8:32 PM

Read Original